Mayo Clinic has signed an agreement with Rheonix to collaborate on the performance of a genotyping test for warfarin sensitivity in clinical and research settings.
The test will be offered through Mayo Clinic’s reference laboratory – Mayo Medical Laboratories – to clients throughout the world.
Mayo Medical Laboratories associate professor Dennis Kane said the anticoagulant warfarin (Coumadin) is prescribed to prevent and treat the formation of blood clots.
"The genetic test enables physicians to administer suitable doses of warfarin individualized to each patient and to identify if they are at risk for forming blood clots due to subtherapeutic dosing, or at risk of severe bleeding due to overdosing of warfarin," Kane said .
Rheonix president Tony Eisenhut said this collaboration brings reality to the long-promised potential of pharmacogenomic testing for pharmaceuticals and for next-generation pharmaceutical development.